Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION After a CMO 483 that maps to the NDA CMC module, CMC comparability package for a site change is what 505(b)(2) development lead can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend Proceed under protocol from CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a CMO 483 that maps to the NDA CMC module. 3. A CMO 483 that maps to the NDA CMC module never reached the population in CMC comparability package for a site change — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the 505(b)(2) bridge is for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in CMC comparability package for a site change, then the action for 505(b)(2) development lead - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal